A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy

Emily J. Pomeroy, John T. Hunzeker, Mitchell G. Kluesner, Walker S. Lahr, Branden A. Smeester, Margaret R. Crosby, Cara lin Lonetree, Kenta Yamamoto, Laura Bendzick, Jeffrey S. Miller, Melissa A. Geller, Bruce Walcheck, Martin Felices, Beau R. Webber, Timothy K. Starr, Branden S. Moriarity

Research output: Contribution to journalArticlepeer-review

61 Scopus citations

Abstract

Enhancing natural killer (NK) cell cytotoxicity could lead to improved cancer immunotherapy. In this issue of Molecular Therapy, Pomeroy et al. describe an efficient method for editing the genome of primary human NK cells using CRISPR/Cas9. The authors target genes using this method to enhance NK cell anti-tumor function.

Original languageEnglish (US)
Pages (from-to)52-63
Number of pages12
JournalMolecular Therapy
Volume28
Issue number1
DOIs
StatePublished - Jan 8 2020

Bibliographical note

Funding Information:
T.S. is supported by funds from the Jan Chorzempa Cancer Research Endowed Fund, the Masonic Cancer Center's Translational Working Group Grant, the Randy Shaver Cancer Research and Community Fund, departmental funds, and institutional grants to MCC from NIH/NCI P30CA07759821 and CTSI from NCATS UL1TR00249402. We acknowledge the University of Minnesota Genomics Center, the Minnesota Supercomputing Institute, and the Masonic Cancer Center for their support of this research. B.S.M. is supported by funds from NIH/NCI R21CA216652 and U54CA232561 and the Children's Cancer Research Fund. T.K.S. is supported by funds from the Jan Chorzempa Cancer Research Endowed Fund, the Masonic Cancer Center's Translational Working Group Grant, the Randy Shaver Cancer Research and Community Fund, departmental funds, and institutional grants to MCC from NIH/NCI P30CA07759821 and CTSI from NCATS UL1TR00249402.

Funding Information:
T.S. is supported by funds from the Jan Chorzempa Cancer Research Endowed Fund, the Masonic Cancer Center's Translational Working Group Grant, the Randy Shaver Cancer Research and Community Fund , departmental funds, and institutional grants to MCC from  NIH/NCI P30CA07759821 and CTSI from NCATS UL1TR00249402 . We acknowledge the University of Minnesota Genomics Center , the Minnesota Supercomputing Institute , and the Masonic Cancer Center for their support of this research. B.S.M. is supported by funds from NIH/NCI R21CA216652 and U54CA232561 and the Children's Cancer Research Fund. T.K.S. is supported by funds from the Jan Chorzempa Cancer Research Endowed Fund, the Masonic Cancer Center’s Translational Working Group Grant, the Randy Shaver Cancer Research and Community Fund, departmental funds, and institutional grants to MCC from NIH/NCI P30CA07759821 and CTSI from NCATS UL1TR00249402 .

Publisher Copyright:
© 2019 The American Society of Gene and Cell Therapy

Keywords

  • ADAM17
  • CRISPR
  • NK cells
  • PD1
  • immunotherapy

Fingerprint

Dive into the research topics of 'A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy'. Together they form a unique fingerprint.

Cite this